This indicates that c-Myc overexpression induces sensitivity to TH588 or TH1579 treatment, which could be used clinically, especially in cancers with known c-Myc deregulation such as aggressive prostate cancer, ovary cancer and breast cancer [26]. Here, MYC is linked to prostate carcinoma.